Silence Therapeutics (SLN) Proxy filing summary

Executive summary

• The 2026 Annual General Meeting (AGM) will be held as a hybrid event on June 16, 2026, allowing participation both in person and electronically.

• Shareholders will vote on nine ordinary resolutions, including director re-appointments, executive compensation, auditor appointments, and adoption of annual reports.

• The board recommends voting in favor of all resolutions and emphasizes the importance of shareholder participation.

Voting matters and shareholder proposals

• Resolutions include re-appointment of two directors, advisory approval of executive compensation, ratification of PricewaterhouseCoopers LLP as auditors, adoption of annual accounts, approval of the directors' remuneration report, and application of takeover protections.

• Voting is by poll, with a simple majority required for passage; shareholders of record as of June 12, 2026, are eligible to vote.

• Shareholders can submit proposals for future meetings if they meet statutory thresholds.

Board of directors and corporate governance

• The board consists of five directors, with a majority deemed independent under Nasdaq rules.

• Committees include Audit & Risk, Remuneration, and Nominations, each composed of independent directors.

• The board chair is separate from the CEO role, supporting independent oversight.

• The nominations committee regularly reviews board composition and considers shareholder recommendations for director nominees.